<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepat Mon</journal-id><journal-id journal-id-type="iso-abbrev">Hepat Mon</journal-id><journal-id journal-id-type="doi">10.5812/hepatmon</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Hepatitis Monthly</journal-title></journal-title-group><issn pub-type="ppub">1735-143X</issn><issn pub-type="epub">1735-3408</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.5812/hepatmon.29052v2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Long</surname><given-names>Li-Hui</given-names></name><xref ref-type="aff" rid="aff64092">1</xref><xref ref-type="corresp" rid="cor64093">*</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Cai-Qin</given-names></name><xref ref-type="aff" rid="aff64092">1</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Jun-Feng</given-names></name><xref ref-type="aff" rid="aff64092">1</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Juan-Ni</given-names></name><xref ref-type="aff" rid="aff64092">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff64094">2</xref></contrib></contrib-group><aff id="aff64092"><label>1</label>Department of Pharmacy, the First Affiliated Hospital of Xi&#x02019;an Medical College, Xi&#x02019;an, Shaanxi 710077, China</aff><aff id="aff64094"><label>2</label>Research Division, the First Affiliated Hospital of Xi&#x02019;an Medical College, Xi&#x02019;an, Shaanxi 710077, China</aff><author-notes><corresp id="cor64093"><label>*</label>Corresponding Author: Li-Hui Long, Department of Pharmacy, the First Affiliated Hospital of Xi&#x02019;an Medical College, Xi&#x02019;an, Shaanxi 710077, China. Tel: +86-2984277599, Fax: +86-2984277599, E-mail: <email>llhbjd@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2015</year></pub-date><volume>15</volume><issue>7</issue><elocation-id>e29052</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>17</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Kowsar Corp.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Context:</title><p>To systematically evaluate the effects of hepatoprotective agents, when delivered either alone or in combination with other antiviral or non-antiviral drugs in patients with hepatitis B and hepatic fibrosis.</p></sec><sec><title>Objectives:</title><p>The current randomized controlled clinical trials aimed to evaluate the efficacy of combinations of antiviral and non-antiviral hepatoprotective agents on indexes of liver function and liver fibrosis in patients with hepatitis B.</p></sec><sec><title>Data Sources:</title><p>Published literatures in Chinese and English on hepatoprotective treatment strategies for chronic hepatitis B and liver fibrosis were searched in three databases and randomized controlled clinical trials were selected. </p></sec><sec><title>Study Selection:</title><p>Data were extracted according to a variety of inclusion and exclusion criteria. Meta-analysis was employed to analyze the data.</p></sec><sec><title>Results:</title><p>A total of 22 randomized controlled trials encompassing 1,714 cases were considered in the meta-analysis. The obtained results indicated that the combination of antiviral drug and hepatoprotective agent was better than antiviral drug alone to improve liver function. Similarly, regarding liver fibrosis, using two different hepatoprotective agents was better than using one agent. The normalization rates of Aminotransferase (ALT) and total Bilirubin (TBil) were improved 25.7% by two hepatoprotective agents compared to the single agent. Acetylcysteine was superior to ursodeoxycholic acid or silibinin to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine or silibinin to reduce TBIL.</p></sec><sec><title>Conclusions:</title><p>Hepatoprotective agents combined with antiviral drugs can significantly improve liver function and liver fibrosis parameters in patients with hepatitis B.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Hepatitis B</kwd><kwd>Liver Cirrhosis</kwd><kwd>Meta-Analysis</kwd><kwd>Ursodeoxycholic Acid (UDCA)</kwd><kwd>Silibinin</kwd><kwd>Acetylcysteine</kwd></kwd-group></article-meta></front><body><sec id="sec110783"><title>1. Context</title><p>At present, Hepatitis B Virus (HBV) infection is an important public health problem worldwide. Hepatitis B can lead to serious liver diseases, including cirrhosis, liver cancer. In China, approximately 120 million people are infected with the Hepatitis B Virus (<xref rid="A29052R1" ref-type="bibr">1</xref>). Alavian et al. reported that about 1 million people are infected with HBV in Iran, and 15% to 40% of the patients with hepatitis B may develop cirrhosis or liver cancer (<xref rid="A29052R2" ref-type="bibr">2</xref>). Liver fibrosis is a healing response, but the excessive accumulation of extracellular matrix (ECM) components in the liver often leads to severe forms of liver fibrosis, and ultimately cirrhosis with liver dysfunction (<xref rid="A29052R3" ref-type="bibr">3</xref>-<xref rid="A29052R5" ref-type="bibr">5</xref>). Early cirrhosis may be reversible. Therefore, prompt diagnosis and intervention are critical in limiting disease progression (<xref rid="A29052R6" ref-type="bibr">6</xref>). Clinically, the existing hepatoprotective agents include Ursodesoxycholic acid (UDCA), silibinin, and N-acetylcysteine (NAC).</p><p>UDCA is a hydrophilic bile acid, which alters the ratio of hydrophilic-to-hydrophobic components in the bile acid pool. It promotes the secretion of endogenous bile acids such as chenodeoxycholic and lithocholic acid, and improves cholestasis. UDCA is mainly used to treat primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic liver disease, the efficacy is certain. Some studies reported that UDCA protects liver cell membrane and enhances immune function. These mechanisms may be related to the ability of ursodeoxycholic acid to regulate cell cycle, apoptosis and protein biosynthesis of liver cells. Alternatively, the increased pool of hydrophilic bile acid and the stability of the cell membrane may play an important protective role (<xref rid="A29052R7" ref-type="bibr">7</xref>, <xref rid="A29052R8" ref-type="bibr">8</xref>). UDCA, which causes minimal damage and is non-toxic to liver cells, is an effective hepatoprotective agent and cholagogue (<xref rid="A29052R9" ref-type="bibr">9</xref>). Results of long-term observational studies showed that ursodeoxycholic acid can significantly reduce the development of hepatic fibrosis (<xref rid="A29052R8" ref-type="bibr">8</xref>, <xref rid="A29052R10" ref-type="bibr">10</xref>, <xref rid="A29052R11" ref-type="bibr">11</xref>).</p><p>Silibinin is derived from milk thistle, an important medicinal plant that is roots, leaves and seeds exert a variety of therapeutic effects, including hepatoprotective, antioxidant, and anti-lipogenic properties (<xref rid="A29052R12" ref-type="bibr">12</xref>). In the United States and Europe, about 65% of patients with liver disease use Chinese medical preparations which include milk thistle as their most common ingredient (<xref rid="A29052R13" ref-type="bibr">13</xref>). Silymarin, a mixture of flavonoids and wood ester pigment compounds, is extracted from milk thistle seeds. Silymarin contains silibinin, silychristin, and silymarin Ning with a large amount of silibinin. it is noteworthy that, silibinin is the main active ingredient of silymarin (<xref rid="A29052R14" ref-type="bibr">14</xref>). In recent years, silibinin has been used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic liver disease (<xref rid="A29052R15" ref-type="bibr">15</xref>).</p><p>N-acetylcysteine (NAC) is an intracellular glutathione precursor, which can enhance the activity of glutathione transferase and promote the detoxification of free radicals. nitric oxide (NO) and its metabolite can improve microcirculation, increase tissue oxygen, and enhance the repair of damaged tissue (<xref rid="A29052R16" ref-type="bibr">16</xref>, <xref rid="A29052R17" ref-type="bibr">17</xref>). In recent years, clinical studies have demonstrated that NAC is not only effective to treat liver failure caused by excessive acetaminophen (paracetamol), but is also useful for liver disease arising from other causes (<xref rid="A29052R18" ref-type="bibr">18</xref>). NAC reduces serum Total Bilirubin (TBil) and aminotransferases, and increases Prothrombin activity (PTA) in patients with severe chronic hepatitis B (<xref rid="A29052R19" ref-type="bibr">19</xref>).</p></sec><sec id="sec110784"><title>2. Objectives</title><p>The current study aimed to search randomized controlled clinical trials to evaluate the efficacy of antiviral and non-antiviral hepatoprotective agents combinations on the indexes of liver function and liver fibrosis in patients with hepatitis B.</p></sec><sec id="sec110789"><title>3. Data Sources</title><p>Papers written in either English or Chinese describing the use of hepatoprotective agents to treat hepatitis and liver fibrosis were retrieved. Using &#x0201c;chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)&#x0201d;, the study retrieved papers indexed in the China national knowledge internet (CNKI) (2000 - 2012), Pubmed (19832013), Embase (2000 - 2013) and Cochrane databases (1992 - 2012).</p></sec><sec id="sec110792"><title>4. Study Selection</title><sec id="sec110787"><title>4.1. Inclusion and Exclusion Criteria</title><sec id="sec110785"><title>4.1.1. Inclusion Criteria</title><p>Hepatitis B infection or liver fibrosis; chronic hepatitis B was diagnosed if HBV history or HBV markers were persistently positive for more than six months and serum alanine aminotransferase levels exceeded 80 IU/L, and hepatic fibrosis was estimated by indexes containing the following markers: HA, LN, C-IV, PIIIP (<xref rid="A29052R13" ref-type="bibr">13</xref>). Results indicators including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), TBIL, gamma-Glutamyl Transpeptidase (&#x003b3;-GGT), Alkaline Phosphatase (ALP), Hyaluronic acid (HA), Laminin (LN), Collagen type IV (CIV), and Procollagen III peptide (PIIIP). Trials were limited to those comparing the efficacy of different drugs or placebo.</p></sec><sec id="sec110786"><title>4.1.2. Exclusion Criteria</title><p>Studies in which non-protective liver drugs were used to treat viral hepatitis or liver fibrosis; animal experiments and reviewed papers that did not contain clinical data; pregnant and lactating female patients with liver disease. The therapy course was less than three weeks; liver biochemical markers were normal.</p></sec></sec><sec id="sec110788"><title>4.2. Outcome Indicators</title><p>Outcomes were reported in terms of efficacy as follows: 1) Markedly effective: patients underwent full recovery or exhibited significant improvements in their clinical symptoms; levels of ALT, AST, GGT, TBIL and other basic indicators of liver function were restored to within the normal range. 2) Effective: moderate improvement of clinical symptoms, signs and liver function. 3) Ineffective: no obvious improvement or exacerbation of symptoms, signs and liver function indexes.</p></sec><sec id="sec110791"><title>4.3. Statistical Analysis</title><p>RevMan5.2 software was used to analyze the data. For classified data, risk ratio (RR) and 95% confidence interval (95% CI) were used. For continuous data, weighted mean difference (WMD) and 95% CI were used. If I2 &#x0003c; 50%, the test was considered uniform with no statistically significant heterogeneity, the fixed effects model was used if I2 &#x0003e; 50%, a random effects model was used. A Funnel plot was used to evaluate possible publication bias.</p></sec></sec><sec id="sec110772"><title>5. Data Extraction</title><p>Two authors discussed all data sets before extracting them from the published literature. To avoid subjective bias, names of the authors, publications, year, and country were omitted during the data extraction process. Retrieved data included: (1) liver biochemical indicators: ALT (U/L), GGT (U/L), ALP (U/L) and TBIL (U/L); (2) liver fibrosis markers: HA (&#x003bc;g/L), LN (&#x003bc;g/L), IV-C (&#x003bc;g/L) and PIIIP (&#x003bc;g/L). Disagreements were resolved by discussion and consensus.</p></sec><sec id="sec110801"><title>6. Results</title><sec id="sec110793"><title>6.1. Retrieval Results</title><p>Initially, 245 papers were retrieved by screening the title, abstract, and inclusion and exclusion criteria. Finally, 22 standard randomized controlled trials were included, with a total of 1,756 subjects, among whom 893 subjects were in the treated group, and 821 subjects were in the control group (<xref ref-type="table" rid="tbl28482">Table 1</xref>).</p><table-wrap id="tbl28482" orientation="portrait" position="float"><label>Table 1.</label><caption><title> Basic Characteristics of the Included Studies <sup><xref ref-type="table-fn" rid="fn27897">a</xref></sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;vertical-align: top;" rowspan="1" colspan="1">Included Studies</th><th style="border-bottom: solid thin;" colspan="2" rowspan="1">Cases</th><th style="border-bottom: solid thin;" colspan="2" rowspan="1">Intervening Measures</th><th style="vertical-align: top;" rowspan="1" colspan="1">Course of Treatment</th><th style="vertical-align: top;" rowspan="1" colspan="1">Efficacy of Indicators</th></tr><tr><th style="text-align: left;" rowspan="1" colspan="1"/><th style="vertical-align: top;" rowspan="1" colspan="1">Experimental Group</th><th style="vertical-align: top;" rowspan="1" colspan="1">Control Group</th><th style="vertical-align: top;" rowspan="1" colspan="1">Experimental Group</th><th style="vertical-align: top;" rowspan="1" colspan="1">Control Group</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Xia et al. (</bold><xref rid="A29052R20" ref-type="bibr">20</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">58</td><td style="text-align: center;" rowspan="1" colspan="1">57</td><td style="text-align: center;" rowspan="1" colspan="1">NAC (8 g/d) + basic treatment</td><td style="text-align: center;" rowspan="1" colspan="1">Basic treatment (Potassium magnesium aspartate 2 g/d + promote the liver cell auxin 0.1 g/d + plasma 200 ml qod + other symptomatic and supportive treatments)</td><td style="text-align: center;" rowspan="1" colspan="1">30 d</td><td style="text-align: center;" rowspan="1" colspan="1">TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Shi et al. (</bold><xref rid="A29052R21" ref-type="bibr">21</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">20</td><td style="text-align: center;" rowspan="1" colspan="1">20</td><td style="text-align: center;" rowspan="1" colspan="1">NAC (8 g/d) + basic treatment</td><td style="text-align: center;" rowspan="1" colspan="1">Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments)</td><td style="text-align: center;" rowspan="1" colspan="1">45 d</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Wang et al. (</bold><xref rid="A29052R19" ref-type="bibr">19</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">50</td><td style="text-align: center;" rowspan="1" colspan="1">25</td><td style="text-align: center;" rowspan="1" colspan="1">NAC (8 g/d) + GSH (1.2 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">GSH (1.2 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">28 d</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Shohrati et al. (</bold><xref rid="A29052R22" ref-type="bibr">22</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">18</td><td style="text-align: center;" rowspan="1" colspan="1">20</td><td style="text-align: center;" rowspan="1" colspan="1">NAC (1.2 g/d) + basic treatment</td><td style="text-align: center;" rowspan="1" colspan="1">Basic treatment (lamivudine + pegylated interferon + adefovir)</td><td style="text-align: center;" rowspan="1" colspan="1">45 d</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, ALP, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Wu et al. (</bold><xref rid="A29052R23" ref-type="bibr">23</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">72</td><td style="text-align: center;" rowspan="1" colspan="1">72</td><td style="text-align: center;" rowspan="1" colspan="1">NAC(8 g/d) + basic treatment</td><td style="text-align: center;" rowspan="1" colspan="1">Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments)</td><td style="text-align: center;" rowspan="1" colspan="1">45 d</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Wang et al. (</bold><xref rid="A29052R24" ref-type="bibr">24</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">42</td><td style="text-align: center;" rowspan="1" colspan="1">42</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (0.5 g/d) + GSH (1.2 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Yinzhihuang (30 ml/d)</td><td style="text-align: center;" rowspan="1" colspan="1">8 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, GGT, ALP, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Fabris et al. (</bold><xref rid="A29052R25" ref-type="bibr">25</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">40</td><td style="text-align: center;" rowspan="1" colspan="1">39</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (0.6 g/d) + lactulose (100-200 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Lactulose (100 - 200 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">3 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, GGT, ALP, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Angulo et al. (</bold><xref rid="A29052R26" ref-type="bibr">26</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">21</td><td style="text-align: center;" rowspan="1" colspan="1">16</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (13 - 15 mg/kg/d)</td><td style="text-align: center;" rowspan="1" colspan="1">D-penicillamine (the dosage was unclear)</td><td style="text-align: center;" rowspan="1" colspan="1">24 w</td><td style="text-align: center;" rowspan="1" colspan="1">AST, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Cao et al. (</bold><xref rid="A29052R27" ref-type="bibr">27</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">53</td><td style="text-align: center;" rowspan="1" colspan="1">47</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (0.75 g/d) + Ademethionine (1.0 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Kuhuang injection (60 ml/d)</td><td style="text-align: center;" rowspan="1" colspan="1">4 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, GGT, ALP, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Qureshi et al. (</bold><xref rid="A29052R28" ref-type="bibr">28</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">18</td><td style="text-align: center;" rowspan="1" colspan="1">12</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (0.5 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Placebo (unclear)</td><td style="text-align: center;" rowspan="1" colspan="1">12 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Ratziu et al. (</bold><xref rid="A29052R29" ref-type="bibr">29</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">62</td><td style="text-align: center;" rowspan="1" colspan="1">64</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (0.5 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Placebo (unclear)</td><td style="text-align: center;" rowspan="1" colspan="1">48 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, GGT, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Tkacz et al. (</bold><xref rid="A29052R12" ref-type="bibr">12</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">45</td><td style="text-align: center;" rowspan="1" colspan="1">15</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.42 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Placebo (unclear)</td><td style="text-align: center;" rowspan="1" colspan="1">45 d</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, TBIL</td></tr><tr style="vertical-align: top;"><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Flisiak et al. (</bold><xref rid="A29052R30" ref-type="bibr">30</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">15</td><td style="text-align: center;" rowspan="1" colspan="1">16</td><td style="text-align: center;" rowspan="1" colspan="1">Misoprostol (0.8 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.21 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">12 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Flisiak et al. (</bold><xref rid="A29052R31" ref-type="bibr">31</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">25</td><td style="text-align: center;" rowspan="1" colspan="1">25</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.21 g/d) + misoprostol (0.8 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Placebo (unclear)</td><td style="text-align: center;" rowspan="1" colspan="1">24 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, GGT, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Gu et al. (</bold><xref rid="A29052R32" ref-type="bibr">32</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">33</td><td style="text-align: center;" rowspan="1" colspan="1">32</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.6 g/d) + oxymatrine (0.6 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.6 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">12 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Bao et al. (</bold><xref rid="A29052R33" ref-type="bibr">33</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">42</td><td style="text-align: center;" rowspan="1" colspan="1">42</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.36 g/d) + Interferon &#x003b1;-16 (300 million U, q.o.d.)</td><td style="text-align: center;" rowspan="1" colspan="1">Interferon &#x003b1;-16 (300 million U, qod.)</td><td style="text-align: center;" rowspan="1" colspan="1">12 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST</td></tr><tr style="vertical-align: top;"><td style="vertical-align: middle;" rowspan="1" colspan="1">
<bold>Bao et al. (</bold><xref rid="A29052R34" ref-type="bibr">34</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">86</td><td style="text-align: center;" rowspan="1" colspan="1">86</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.36 g/d) + Lamivudine (0.1 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Lamivudine (0.1 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">48 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, ALP, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Kim et al. (</bold><xref rid="A29052R35" ref-type="bibr">35</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">42</td><td style="text-align: center;" rowspan="1" colspan="1">43</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (0.6 g/d) + Candesartan (0.008 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Candesartan (0.008 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">24 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, GGT, TBIL</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Wang et al. (</bold><xref rid="A29052R36" ref-type="bibr">36</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">45</td><td style="text-align: center;" rowspan="1" colspan="1">44</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.315 g/d) + protect liver treatment + Lamivudine (0.1 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Protect liver treatment (energy mixture, inosine, salvia miltiorrhiza, promoting liver cell growth hormone and vitamin) + Lamivudine (0.1 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">NA</td><td style="text-align: center;" rowspan="1" colspan="1">HA, PC, CIV, LN</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Wu et al. (</bold><xref rid="A29052R37" ref-type="bibr">37</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">40</td><td style="text-align: center;" rowspan="1" colspan="1">40</td><td style="text-align: center;" rowspan="1" colspan="1">UDCA (13-15 mg/kg/d) + Fuzhenghuayu Capsules (4.5 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Fuzhenghuayu Capsules (4.5 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">48 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, GGT, TBIL, ALP, HA, LN, IVC, PIIIP</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Mao et al. (</bold><xref rid="A29052R38" ref-type="bibr">38</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">36</td><td style="text-align: center;" rowspan="1" colspan="1">34</td><td style="text-align: center;" rowspan="1" colspan="1">Tanshinone (0.06 g/d) + Oxymatrine (0.6 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Tanshinone (0.06 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">4 w</td><td style="text-align: center;" rowspan="1" colspan="1">ALT, AST, TBILI, HA, LN, PIIIP, IVC</td></tr><tr style="vertical-align: top;"><td rowspan="1" colspan="1">
<bold>Zhou et al. (</bold><xref rid="A29052R39" ref-type="bibr">39</xref><bold>)</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">30</td><td style="text-align: center;" rowspan="1" colspan="1">30</td><td style="text-align: center;" rowspan="1" colspan="1">Valsartan (0.08 g/d) + Silibinin (0.14 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">Silibinin (0.14 g/d)</td><td style="text-align: center;" rowspan="1" colspan="1">12 w</td><td style="text-align: center;" rowspan="1" colspan="1">HA, LN, IV-C, PIIIP</td></tr></tbody></table><table-wrap-foot><fn id="fn27897"><p><sup>a</sup> Abbreviations: ALT, Alanine aminotransferase Aminotransferase; ALP; alkaline Alkaline phosphatase Phosphatase; AST, aspartate Aspartate aminotransferase Aminotransferase; CIV collagen Collagen type IV; HA, hyaluronic Hyaluronic acid Acid; LN, laminin Laminin; PIIIP, procollagen Procollagen III peptide Peptide; TBIL, total bilirubin; &#x003b3;-GGT, gamma-glutamyl Glutamyl transpeptidase Transpeptidase</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec110794"><title>6.2. Treatment Type</title><p>The meta-analysis groups were: 1) liver protective drug plus antiviral drug versus antiviral drug alone to assess efficacy of altering ALT, AST, ALP and TBIL levels (<xref ref-type="table" rid="tbl28482">Table 1</xref>; <xref ref-type="fig" rid="fig21153">Figure 1</xref>); 2) liver protective drug (treatment group) versus placebo to assess protective effects in terms of ALT and TBIL (<xref ref-type="table" rid="tbl28482">Table 1</xref>; <xref ref-type="fig" rid="fig21157">figures 3</xref> and <xref ref-type="fig" rid="fig21154">4</xref>); 3) combination of two hepatoprotective agents versus a single agent in terms of ALT, AST, ALP, GGT, TBIL (<xref ref-type="table" rid="tbl28482">Table 1</xref>; <xref ref-type="fig" rid="fig21154">Figure 4</xref>); 4) one protective agent versus another in terms of normalization rates of ALT and TBIL (<xref ref-type="table" rid="tbl28482">Table 1</xref>; <xref ref-type="fig" rid="fig21155">Figure 5</xref>); 5) evaluation of the effects of a combination of two kinds of protective agents versus a single protective agent in terms of HA, LN, IV-C and PIIIP (<xref ref-type="table" rid="tbl28482">Table 1</xref>; <xref ref-type="fig" rid="fig21158">figures 6</xref> and <xref ref-type="fig" rid="fig21159">7</xref>) as hepatic fibrosis markers.</p></sec><sec id="sec110795"><title>6.3. Hepatoprotective Drug Combined With Antiviral Drug vs. Antiviral Drug Alone</title><p>Six randomized controlled trials reported on the use of a hepatoprotective drug in combination with an antiviral agent treatment of chronic hepatitis B. The test and control groups included 741 and 645 subjects, respectively. There was a statistically significant heterogeneity between the studies (I2 &#x0003e; 50%), and hence, a random-effects model was used. Meta-analysis showed that using a combination of hepatoprotective and antiviral drugs was more effective than a single antiviral agent to reduce serum levels of ALT, AST, ALP and TBIL. ALT (WMD = -22.98; 95% CI (-34.98, -10.97)), AST (WMD= -26.20; 95% CI [-44.60, -7.81]), ALP (WMD = -56.19; 95% CI [-85.27, -27.11]) and TBIL (WMD= -5.58; 95% CI [-9.50, 1.66]) (<xref ref-type="fig" rid="fig21153">Figure 1</xref>).</p><fig id="fig21153" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Meta-Analysis Forest Plots for Effects on ALT, AST, ALP and TBIL Levels</title><p>In patients with chronic hepatitis B infection treated with combination hepatoprotective and antiviral drug vs. antiviral drug alone. Data are presented as pooled mean difference using a random-effects model and 95% confidence intervals.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i001"/></fig></sec><sec id="sec110796"><title>6.4. Hepatoprotective Agents vs. Placebo</title><p>Five randomized controlled clinical trials reported the effects of three hepatoprotective agents compared with placebo on liver function indexes in patients with chronic hepatitis B, including ALT and TBIL. In these trials, the control and treatment groups included 144 and 140 subjects, respectively; since there was no significant heterogeneity between the studies (I2 &#x0003c; 50%), a fixed effect model was applied. Meta-analysis showed that all three hepatoprotective agents significantly decreased ALT levels in patients with hepatitis B. NAC was associated with greater efficacy compared to UDCA and silibinin. The impact of UDCA and silibinin on ALT levels in patients with hepatitis B were considerable: NAC (WMD = -25.66; P = 0.0002, 95% CI [-39.02, -12.31]), UDCA (WMD = -22.32; P = 0.03, 95% CI [-42.28, -2.36]), silibinin (WMD = -22.40; P = 0.11, 95% CI [-49.52, 4.72]) (<xref ref-type="fig" rid="fig21156">Figure 2</xref>).</p><fig id="fig21156" orientation="portrait" position="float"><label>Figure 2.</label><caption><title>Meta-Analysis Forest Plots Indicating Reduced Amounts of ALT</title><p>In patients with chronic hepatitis B infection treated with hepatoprotective drugs vs. placebo. Data are presented as pooled mean difference using a random-effect model and 95 % confidence intervals.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i002"/></fig><p>UDCA was superior over NAC and silibinin to reduce TBIL in patients with hepatitis B. Meta-analysis showed that NAC (WMD = -2.56; P = 95% CI [-4.95, -0.17]), UDCA (WMD = -3.48; 95% CI [-7.37, -0.31]), silibinin (WMD = -2.09; 95% CI [-8.70, 4.52]). However, the differences were not statistically significant (I2 = 0%) using a fixed-effects model (<xref ref-type="fig" rid="fig21157">Figure 3</xref>).</p><fig id="fig21157" orientation="portrait" position="float"><label>Figure 3.</label><caption><title>Meta-Analysis Forest Plots Describing the Effects of Hepatoprotective Agents vs. Placebo on TBIL Levels</title><p>In patients with chronic hepatitis B infection. Data are presented as pooled relative risks using a fixed-effect model and 95 % confidence intervals.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i003"/></fig></sec><sec id="sec110797"><title>6.5. Two Kinds of Hepatoprotective Agents vs. a Single Hepatoprotective Agent</title><p>Five randomized controlled clinical trials were employed to test the efficacy of two hepatoprotective agents compared to only one to treat patients with chronic hepatitis B. There were 618 subjects in the two hepatoprotective agents, and the single hepatoprotective agent groups, respectively. The heterogeneity between the studies was statistically significant (I2 &#x0003e; 50%). Using a random effects model, meta-analysis showed that the two hepatoprotective agents group was better than the single agent to reduce ALT, AST, GGT, ALP and TBIL levels in patients with hepatitis B. ALT (WMD=-31.44; 95% CI [-48.57,-14.32]), AST (WMD = -14.54; 95% CI [-29.24, 0.16]), GGT (WMD = -26.98; 95% CI [-54.66&#x0ff0c;0.70]), ALP (WMD = -29.86; 95% CI [-52.65, -7.07]), TBIL (WMD = -4.84; 95% CI [-9.86, 0.18]) (<xref ref-type="fig" rid="fig21154">Figure 4</xref>).</p><fig id="fig21154" orientation="portrait" position="float"><label>Figure 4.</label><caption><title>Meta-Analysis Forest Plots for Effects</title><p>In patients with chronic hepatitis B infection treated with the combination of two liver protective drugs vs. one liver protective drug. Data are presented as pooled mean difference using a random-effect model, and 95% confidence intervals.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i004"/></fig></sec><sec id="sec110798"><title>6.6. Effects of two Versus one Hepatoprotective Agent on Recovery of Liver Function in Patients With Hepatitis B</title><p>Three randomized controlled clinical trials reported the effects of combining two hepatoprotective drugs compared to a single agent on the recovery rate of liver indicators in patients with hepatitis B; 173 subjects who used a combination of two agents were compared to 123 subjects who used only one agent. The heterogeneity between the studies was statistically significant (I2 = 0%, P = 0.98). Therefore, a fixed-effects model was used. Compared with the single agent group, meta-analysis showed that using a combination of two hepatoprotective drugs was more effective than only one in restoring liver indicators to normal levels (two hepatoprotective agents group vs. single hepatoprotective agent group = 75.2% vs. 49.5%). ALT (72.3% vs. 48.7%, RR = 1.44, 95% CI [1.01, 2.04]), TBIL (77.8% vs. 50%, RR = 1.53, 95% CI [1.21, 1.95]). The recovery rate of the group that used two hepatoprotective agents was 25.7% higher than the one treated by a single agent, (RR = 1.50, P &#x0003c; 0.0001, 95% CI [1.23, 1.83]) (<xref ref-type="fig" rid="fig21155">Figure 5</xref>).</p><fig id="fig21155" orientation="portrait" position="float"><label>Figure 5.</label><caption><title>Meta-Analysis Forest Plots Indicating the Normalization Rates of ALT and TBIL</title><p>In patients with chronic hepatitis B infection treated with two vs. one hepatoprotective agent. Data are presented as pooled relative risks, adopted fixed-effect model and 95 % confidence intervals, by trial.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i005"/></fig></sec><sec id="sec110799"><title>6.7. Effects of Hepatoprotective Agents on Liver Fibrosis Indexes in Patients With Hepatitis B</title><p>Three randomized controlled clinical trials reported the effects of hepatoprotective agents on liver fibrosis markers, HA, IV-C and PIIIP. From the three studies, the test and control groups consisted of 121 and 118 subjects, respectively. The heterogeneity between the studies was statistically significant (I2 &#x0003e; 50%). Thus, a random-effects model was used. The results indicated that hepatoprotective agents were indeed associated with improved indices of hepatic fibrosis compared to placebo: HA (WMD = -55.65, 95% CI [-75.00, -36.31]), IV-C (WMD = -29.23, 95% CI [-41.21, -17.25]), PIIIP (WMD = -53.79, 95% CI [-69.03, -38.55]) (<xref ref-type="fig" rid="fig21158">Figure 6</xref>).</p><fig id="fig21158" orientation="portrait" position="float"><label>Figure 6.</label><caption><title>Meta-Analysis With Forest Plots Effects of two Hepatoprotective Agents vs. a Single Hepatoprotective Agent on Levels of HA, IV-C and PIIIP</title><p>In patients with liver fibrosis. Data are presented as pooled mean difference using a random-effects model and 95 % confidence intervals, by trials.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i006"/></fig><p>Four randomized controlled clinical trials reported the effects of combined hepatoprotective agents versus a single agent on the liver fibrosis index, LN. The group representing the combined hepatoprotective agents included 151 subjects, whereas the single hepatoprotective agent group had 148 subjects. There was no significant heterogeneity (I2 &#x0003c; 50%); therefore, a fixed-effects model was used. Meta-analysis showed that the two hepatoprotective agents was superior to the single one in terms of reducing LN levels (WMD = -33.91, 95% CI [-40.51, -27.31]) (<xref ref-type="fig" rid="fig21159">Figure 7</xref>).</p><fig id="fig21159" orientation="portrait" position="float"><label>Figure 7.</label><caption><title>Meta-Analysis Forest Plots of LN Levels in Patients With Liver Fibrosis Infection Treated with Two vs. one Hepatoprotective Agents</title><p>Data are presented as pooled mean difference using a random-effects model, and 95% confidence intervals.</p></caption><graphic xlink:href="hepatmon-15-07-29052-i007"/></fig></sec><sec id="sec110800"><title>6.8. Assessment of Publication Bias</title><p>A Funnel plot analysis of bias among 12 trials on the effects of hepatoprotective agents on normalization of ALT, AST and TBIL was conducted, in patients with hepatitis B (<xref ref-type="fig" rid="fig21160">Figure 8</xref>). The Funnel plot showed that the distribution of the samples were asymmetrical, suggesting that some of the test methodologies may have been of low quality, and publication bias may have been present.</p><fig id="fig21160" orientation="portrait" position="float"><label>Figure 8.</label><caption><title>A Funnel plot analysis of the effects of hepatoprotective agents on normalization of ALT, AST and TBIL, in patients with hepatitis B</title></caption><graphic xlink:href="hepatmon-15-07-29052-i008"/></fig></sec></sec><sec id="sec110802"><title>7. Discussion</title><p> The current model is expected to maximize long-term treatment of severe liver disease caused by HBV infection to suppress the virus, improve inflammation and necrosis, and deliver adjuvant therapy to manage complications.</p><p>The results of the current study showed that after a certain treatment course of a combined hepatoprotective and antiviral drugs, liver function and fibrosis index decreased in most of the subjects. Combination therapy was more effective than a single hepatoprotective agent to reduce liver cell damage, promote the liver cell membrane and promote the recovery of liver function, and it may delay the formation and development of hepatic fibrosis (<xref rid="A29052R38" ref-type="bibr">38</xref>). Some studies showed a synergistic effect between hepatoprotective agents and antiviral drugs. It may be related to the improvement in drug tolerance due to hepatoprotective agents in patients with hepatitis B (<xref rid="A29052R34" ref-type="bibr">34</xref>, <xref rid="A29052R40" ref-type="bibr">40</xref>). In 2006, Qureshi et al reported that large doses of ursodeoxycholic acid reduces ALT levels in patients with hepatitis B (<xref rid="A29052R28" ref-type="bibr">28</xref>). The meta-analysis of the current study showed that acetylcysteine, ursodeoxycholic acid and silibinin significantly reduced ALT, and were a liver function marker in patients with hepatitis B. The reduction in ALT levels by acetylcysteine was better than ursodeoxycholic acid and silibinin. This may be related to the ability of acetylcysteine to inhibit the expression of serum II-18, IFN-&#x003b3; and NO in the patients with hepatitis B. Some studies stated that acetylcysteine should be used, and that it was more beneficial in early stages of liver disease (<xref rid="A29052R21" ref-type="bibr">21</xref>).</p><p>The limitations of the study included the retrospective nature, variability of the quantity, quality and sources of the hepatoprotective agents, and the variability, and effectiveness of the antiviral agents. High-quality multi-center, large sample, randomized, double-blind and controlled clinical trials are necessary to confirm the current observations.</p><p>In conclusion, hepatoprotective drugs can effectively improve serum liver markers in patients with liver fibrosis when combined with antiviral or other hepatoprotective agents.</p></sec></body><back><ack><p>The current work was supported by the social development research project of Shaanxi science and technology agency (No. 2012k14-04-01) and the project of Xi&#x02019;an medical college (No. XYFY11-02).</p></ack><fn-group><fn id="afn40523" fn-type="other"><p><bold>Authors&#x02019; Contributions:</bold>Authors had equal contribution.</p></fn><fn id="afn40524" fn-type="supported-by"><p><bold>Funding/Support:</bold>The current research was financially supported by Shaanxi Science and Technology Agency (No. 2012k14-04-01); the project of Xi&#x02019;an Medical College affiliated hospital (No. XYFY11-02).</p></fn></fn-group><ref-list><title>References</title><ref id="A29052R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>GN</given-names></name><name><surname>Chen</surname><given-names>LH</given-names></name></person-group><article-title>Glycyrrhizin injection combined with Danshen injection observe the effect of hepatitis B liver fibrosis.</article-title><source>J Tibetan Med.</source><year>2010</year><volume>31</volume><issue>1</issue><fpage>24</fpage><lpage>5</lpage></element-citation></ref><ref id="A29052R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Tabatabaei</surname><given-names>SV</given-names></name><name><surname>Ghadimi</surname><given-names>T</given-names></name><name><surname>Beedrapour</surname><given-names>F</given-names></name><name><surname>Kafi-Abad</surname><given-names>SA</given-names></name><name><surname>Gharehbaghian</surname><given-names>A</given-names></name><etal>et al.</etal></person-group><article-title>Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study.</article-title><source>Int J Prev Med.</source><year>2012</year><volume>3</volume><issue>11</issue><fpage>770</fpage><lpage>5</lpage><?supplied-pmid 23189228?><pub-id pub-id-type="pmid">23189228</pub-id></element-citation></ref><ref id="A29052R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bataller</surname><given-names>R</given-names></name><name><surname>Brenner</surname><given-names>DA</given-names></name></person-group><article-title>Liver fibrosis.</article-title><source>J Clin Invest.</source><year>2005</year><volume>115</volume><issue>2</issue><fpage>209</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1172/JCI24282</pub-id><?supplied-pmid 15690074?><pub-id pub-id-type="pmid">15690074</pub-id></element-citation></ref><ref id="A29052R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>Mechanisms of hepatic fibrogenesis.</article-title><source>Gastroenterology.</source><year>2008</year><volume>134</volume><issue>6</issue><fpage>1655</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.003</pub-id><?supplied-pmid 18471545?><pub-id pub-id-type="pmid">18471545</pub-id></element-citation></ref><ref id="A29052R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BK</given-names></name><name><surname>Kim do</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Chon</surname><given-names>CY</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><etal>et al.</etal></person-group><article-title>Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients.</article-title><source>Liver Int.</source><year>2010</year><volume>30</volume><issue>4</issue><fpage>546</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2009.02192.x</pub-id><?supplied-pmid 20074094?><pub-id pub-id-type="pmid">20074094</pub-id></element-citation></ref><ref id="A29052R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>WR</given-names></name></person-group><article-title>The global impact of hepatic fibrosis and end-stage liver disease.</article-title><source>Clin Liver Dis.</source><year>2008</year><volume>12</volume><issue>4</issue><fpage>733</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2008.07.007</pub-id><?supplied-pmid 18984463?><pub-id pub-id-type="pmid">18984463</pub-id></element-citation></ref><ref id="A29052R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>XD</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name></person-group><article-title>Observation on the clinical efficiency of adenosine combine with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice.</article-title><source>Chin Hosp Pharm J Dis.</source><year>2003</year><volume>32</volume><issue>6</issue><fpage>481</fpage><lpage>3</lpage></element-citation></ref><ref id="A29052R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>MZ</given-names></name><name><surname>Liang</surname><given-names>CR</given-names></name></person-group><article-title>Clinical Observation of Ademetionine Combined With Ursodeoxycholic Acid in the Treatment ofChronic Severe Cholestatic Hepatitis.</article-title><source>Chin Hosp Pharm Dis.</source><year>2013</year><volume>14</volume><issue>3</issue><fpage>68</fpage><lpage>9</lpage></element-citation></ref><ref id="A29052R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>SS</given-names></name><name><surname>Kang</surname><given-names>HC</given-names></name><name><surname>Won</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>DI</given-names></name></person-group><article-title>Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and nitric oxide in rat microglia.</article-title><source>Arch Pharm Res.</source><year>2003</year><volume>26</volume><issue>12</issue><fpage>1067</fpage><lpage>73</lpage><?supplied-pmid 14723342?><pub-id pub-id-type="pmid">14723342</pub-id></element-citation></ref><ref id="A29052R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekaj</surname><given-names>E</given-names></name><name><surname>Gjata</surname><given-names>A</given-names></name><name><surname>Maxhuni</surname><given-names>M</given-names></name></person-group><article-title>The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study.</article-title><source>BMC Surg.</source><year>2013</year><volume>13</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/1471-2482-13-38</pub-id><?supplied-pmid 24053627?><pub-id pub-id-type="pmid">24053627</pub-id></element-citation></ref><ref id="A29052R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boberg</surname><given-names>KM</given-names></name><name><surname>Wisloff</surname><given-names>T</given-names></name><name><surname>Kjollesdal</surname><given-names>KS</given-names></name><name><surname>Stovring</surname><given-names>H</given-names></name><name><surname>Kristiansen</surname><given-names>IS</given-names></name></person-group><article-title>Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.</article-title><source>Aliment Pharmacol Ther.</source><year>2013</year><volume>38</volume><issue>7</issue><fpage>794</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1111/apt.12435</pub-id><?supplied-pmid 23915021?><pub-id pub-id-type="pmid">23915021</pub-id></element-citation></ref><ref id="A29052R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkacz</surname><given-names>B</given-names></name><name><surname>Dworniak</surname><given-names>D</given-names></name></person-group><article-title>[Sylimarol in the treatment of acute viral hepatitis].</article-title><source>Wiad Lek.</source><year>1983</year><volume>36</volume><issue>8</issue><fpage>613</fpage><lpage>6</lpage><?supplied-pmid 6353775?><pub-id pub-id-type="pmid">6353775</pub-id></element-citation></ref><ref id="A29052R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>SK</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>ZJ</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>YL</given-names></name><etal>et al.</etal></person-group><article-title>Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B.</article-title><source>Eur J Clin Microbiol Infect Dis.</source><year>2013</year><volume>32</volume><issue>5</issue><fpage>657</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s10096-012-1789-1</pub-id><?supplied-pmid 23247631?><pub-id pub-id-type="pmid">23247631</pub-id></element-citation></ref><ref id="A29052R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>BR</given-names></name><name><surname>Zhao</surname><given-names>YY</given-names></name><name><surname>Xu</surname><given-names>BH</given-names></name><name><surname>Wu</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>CY</given-names></name></person-group><article-title>Research of silymarin extraction and silibinin purification.</article-title><source>Lishizhen Med Materia Med Res.</source><year>2012</year><volume>23</volume><issue>3</issue><fpage>655</fpage><lpage>6</lpage></element-citation></ref><ref id="A29052R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feher</surname><given-names>J</given-names></name><name><surname>Lengyel</surname><given-names>G</given-names></name></person-group><article-title>[Silymarin in the treatment of chronic liver diseases: past and future].</article-title><source>Orv Hetil.</source><year>2008</year><volume>149</volume><issue>51</issue><fpage>2413</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1556/OH.2008.28519</pub-id><?supplied-pmid 19073452?><pub-id pub-id-type="pmid">19073452</pub-id></element-citation></ref><ref id="A29052R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffer</surname><given-names>E</given-names></name><name><surname>Baum</surname><given-names>Y</given-names></name><name><surname>Tabak</surname><given-names>A</given-names></name><name><surname>Taitelman</surname><given-names>U</given-names></name></person-group><article-title>N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity.</article-title><source>Toxicol Letters.</source><year>1996</year><volume>84</volume><issue>1</issue><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0378-4274(95)03446-3</pub-id></element-citation></ref><ref id="A29052R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Wendon</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure.</article-title><source>Hepatology.</source><year>1996</year><volume>23</volume><issue>5</issue><fpage>1067</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1053/jhep.1996.v23.pm0008621135</pub-id><?supplied-pmid 8621135?><pub-id pub-id-type="pmid">8621135</pub-id></element-citation></ref><ref id="A29052R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClain</surname><given-names>CJ</given-names></name><name><surname>Price</surname><given-names>S</given-names></name><name><surname>Barve</surname><given-names>S</given-names></name><name><surname>Devalarja</surname><given-names>R</given-names></name><name><surname>Shedlofsky</surname><given-names>S</given-names></name></person-group><article-title>Acetaminophen hepatotoxicity: An update.</article-title><source>Curr Gastroenterol Rep.</source><year>1999</year><volume>1</volume><issue>1</issue><fpage>42</fpage><lpage>9</lpage><?supplied-pmid 10980926?><pub-id pub-id-type="pmid">10980926</pub-id></element-citation></ref><ref id="A29052R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>XF</given-names></name><name><surname>Guo</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>DZ</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name></person-group><article-title>[A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients].</article-title><source>Zhonghua Gan Zang Bing Za Zhi.</source><year>2008</year><volume>16</volume><issue>7</issue><fpage>487</fpage><lpage>9</lpage><?supplied-pmid 18647523?><pub-id pub-id-type="pmid">18647523</pub-id></element-citation></ref><ref id="A29052R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>G</given-names></name></person-group><article-title>The clinical efficacy observation of acetylcysteine injection on 58 cases of chronic severe hepatitis B.</article-title><source>West Chin Med J.</source><year>2009</year><volume>24</volume><issue>5</issue><fpage>1239</fpage><lpage>40</lpage></element-citation></ref><ref id="A29052R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>XF</given-names></name><name><surname>Guo</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>ZY</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>The clinical curative effect observation of acetylcysteine injection on 40 cases of chronic hepatitis B.</article-title><source>J Chongqing Med Univ.</source><year>2005</year><volume>30</volume><issue>1</issue><fpage>115</fpage><lpage>21</lpage></element-citation></ref><ref id="A29052R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shohrati</surname><given-names>M</given-names></name><name><surname>Dermanaki</surname><given-names>F</given-names></name><name><surname>Babaei</surname><given-names>F</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name></person-group><article-title>Evaluation of the effects of oral N-acetylcysteine and a placebo in paraclinical and oxidative stress parameters of patients with chronic hepatitis B.</article-title><source>Hepat Mon.</source><year>2010</year><volume>10</volume><issue>2</issue><fpage>95</fpage><lpage>100</lpage><?supplied-pmid 22312380?><pub-id pub-id-type="pmid">22312380</pub-id></element-citation></ref><ref id="A29052R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>SH</given-names></name></person-group><article-title>The Clinic Study of N-Acetylcysteine Injection Therapy to Chronic Hepatitis B.</article-title><source>Chongqing Med Univer.</source><year>2004</year><volume>3</volume><fpage>25</fpage><lpage>49</lpage></element-citation></ref><ref id="A29052R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>[Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B].</article-title><source>Zhong Nan Da Xue Xue Bao Yi Xue Ban.</source><year>2010</year><volume>35</volume><issue>2</issue><fpage>171</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1672-7347.2010.02.014</pub-id><?supplied-pmid 20197618?><pub-id pub-id-type="pmid">20197618</pub-id></element-citation></ref><ref id="A29052R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabris</surname><given-names>P</given-names></name><name><surname>Tositti</surname><given-names>G</given-names></name><name><surname>Mazzella</surname><given-names>G</given-names></name><name><surname>Zanetti</surname><given-names>AR</given-names></name><name><surname>Nicolin</surname><given-names>R</given-names></name><name><surname>Pellizzer</surname><given-names>G</given-names></name><etal>et al.</etal></person-group><article-title>Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.</article-title><source>Aliment Pharmacol Ther.</source><year>1999</year><volume>13</volume><issue>9</issue><fpage>1187</fpage><lpage>93</lpage><?supplied-pmid 10468700?><pub-id pub-id-type="pmid">10468700</pub-id></element-citation></ref><ref id="A29052R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angulo</surname><given-names>P</given-names></name><name><surname>Batts</surname><given-names>KP</given-names></name><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Jorgensen</surname><given-names>RA</given-names></name><name><surname>Dickson</surname><given-names>ER</given-names></name><name><surname>Lindor</surname><given-names>KD</given-names></name></person-group><article-title>Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.</article-title><source>Hepatology.</source><year>1999</year><volume>29</volume><issue>3</issue><fpage>644</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/hep.510290301</pub-id><?supplied-pmid 10051462?><pub-id pub-id-type="pmid">10051462</pub-id></element-citation></ref><ref id="A29052R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>CAO</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>XD</given-names></name><name><surname>CHENG</surname><given-names>H</given-names></name><name><surname>HUANG</surname><given-names>S</given-names></name><name><surname>BAI</surname><given-names>T</given-names></name><name><surname>GAN</surname><given-names>H</given-names></name><etal>et al.</etal></person-group><article-title>Observation on the clinical efficiency of adenosine methionine combined with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice.</article-title><source>Chinese J Hos Pharm.</source><year>2013</year><volume>6</volume><fpage>019</fpage></element-citation></ref><ref id="A29052R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>H</given-names></name><name><surname>Mehdi</surname><given-names>I</given-names></name><name><surname>Ahmed</surname><given-names>WU</given-names></name><name><surname>Alam</surname><given-names>SE</given-names></name></person-group><article-title>Role of ursodeoxycholic acid in lowering ALT in chronic liver disease.</article-title><source>J Pak Med Assoc.</source><year>2006</year><volume>56</volume><issue>3</issue><fpage>130</fpage><lpage>1</lpage><?supplied-pmid 16696513?><pub-id pub-id-type="pmid">16696513</pub-id></element-citation></ref><ref id="A29052R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratziu</surname><given-names>V</given-names></name><name><surname>de Ledinghen</surname><given-names>V</given-names></name><name><surname>Oberti</surname><given-names>F</given-names></name><name><surname>Mathurin</surname><given-names>P</given-names></name><name><surname>Wartelle-Bladou</surname><given-names>C</given-names></name><name><surname>Renou</surname><given-names>C</given-names></name><etal>et al.</etal></person-group><article-title>A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.</article-title><source>J Hepatol.</source><year>2011</year><volume>54</volume><issue>5</issue><fpage>1011</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.08.030</pub-id><?supplied-pmid 21145828?><pub-id pub-id-type="pmid">21145828</pub-id></element-citation></ref><ref id="A29052R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flisiak</surname><given-names>R</given-names></name><name><surname>Prokopowicz</surname><given-names>D</given-names></name></person-group><article-title>Effect of misoprostol on serum beta2-microglobulin in the course of viral hepatitis B.</article-title><source>Eur J Gastroenterol Hepatol.</source><year>1999</year><volume>11</volume><issue>11</issue><fpage>1227</fpage><lpage>30</lpage><?supplied-pmid 10563531?><pub-id pub-id-type="pmid">10563531</pub-id></element-citation></ref><ref id="A29052R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flisiak</surname><given-names>R</given-names></name><name><surname>Prokopowicz</surname><given-names>D</given-names></name></person-group><article-title>Effect of misoprostol on the course of viral hepatitis B.</article-title><source>Hepatogastroenterology.</source><year>1997</year><volume>44</volume><issue>17</issue><fpage>1419</fpage><lpage>25</lpage><?supplied-pmid 9356866?><pub-id pub-id-type="pmid">9356866</pub-id></element-citation></ref><ref id="A29052R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>XB</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Hua</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>ZH</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>YF</given-names></name><etal>et al.</etal></person-group><article-title>Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B.</article-title><source>Chin Med J (Engl).</source><year>2012</year><volume>125</volume><issue>8</issue><fpage>1434</fpage><lpage>8</lpage><?supplied-pmid 22613649?><pub-id pub-id-type="pmid">22613649</pub-id></element-citation></ref><ref id="A29052R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>FY</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name></person-group><article-title>Silybin phospholipid complex combinated with interferon treating hepatitis B.</article-title><source>J Cent Plains Med.</source><year>2006</year><volume>33</volume><issue>15</issue><fpage>70</fpage><lpage>1</lpage></element-citation></ref><ref id="A29052R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>FY</given-names></name><name><surname>Qiu</surname><given-names>PY</given-names></name></person-group><article-title>Analyzing the adjunctive therapy of silibinin phospholipid complex treat chronic hepatitis B in 86 cases.</article-title><source>Shandong Med.</source><year>2006</year><volume>26</volume><fpage>26</fpage><lpage>31</lpage></element-citation></ref><ref id="A29052R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Cho</surname><given-names>MY</given-names></name><name><surname>Baik</surname><given-names>SK</given-names></name><name><surname>Jeong</surname><given-names>PH</given-names></name><name><surname>Suk</surname><given-names>KT</given-names></name><name><surname>Jang</surname><given-names>YO</given-names></name><etal>et al.</etal></person-group><article-title>Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study.</article-title><source>Liver Int.</source><year>2012</year><volume>32</volume><issue>6</issue><fpage>977</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2012.02774.x</pub-id><?supplied-pmid 22364262?><pub-id pub-id-type="pmid">22364262</pub-id></element-citation></ref><ref id="A29052R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>YL</given-names></name><name><surname>Xu</surname><given-names>KC</given-names></name></person-group><article-title>[Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B].</article-title><source>Zhongguo Zhong Xi Yi Jie He Za Zhi.</source><year>2006</year><volume>26</volume><issue>11</issue><fpage>978</fpage><lpage>80</lpage><?supplied-pmid 17186724?><pub-id pub-id-type="pmid">17186724</pub-id></element-citation></ref><ref id="A29052R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>DK</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title>[Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the treatment of primary biliary cirrhosis].</article-title><source>Zhongguo Zhong Xi Yi Jie He Za Zhi.</source><year>2012</year><volume>32</volume><issue>11</issue><fpage>1477</fpage><lpage>82</lpage><?supplied-pmid 23359968?><pub-id pub-id-type="pmid">23359968</pub-id></element-citation></ref><ref id="A29052R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>ZY</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>XJ</given-names></name><name><surname>Tao</surname><given-names>LG</given-names></name></person-group><article-title>Tan&#x02161;A, Oxymatrine combined therapy on liver function in patients with chronic hepatitis B and liver fibrosis.</article-title><source>Pract Clin Med.</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>21</fpage><lpage>3</lpage></element-citation></ref><ref id="A29052R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>XY</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>XC</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Clinical effects of valsartan on liver fibrosis indexes in patients with alcoholic liver cirrhosis.</article-title><source>Chin J Integr Trad Western Med Live Dis.</source><year>2014</year><volume>24</volume><issue>2</issue><fpage>85</fpage><lpage>6</lpage></element-citation></ref><ref id="A29052R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gou</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name></person-group><article-title>To observe the effect of interferon &#x003b1;-2b combined with silymarin to treat chronic hepatitis B.</article-title><source>Clin Hepatol.</source><year>2004</year><volume>5</volume><fpage>302</fpage></element-citation></ref></ref-list></back></article>